FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281914> ?p ?o ?g. }

• W4379281914 endingPage "e19532" @default.
• W4379281914 startingPage "e19532" @default.
• W4379281914 abstract "e19532 Background: BTK (Bruton's tyrosine kinase), a central regulator of the B cell receptor signaling pathway, has been targeted for treating a variety of B cell malignancies and autoimmune diseases. The use of the first generation covalent BTK inhibitors (BTKis) have often resulted in the development of resistance, commonly associated with the mutation at the cysteine 481 where the inhibitor binds covalently; therefore, a non-covalent BTKi will offer greater therapeutic benefits. HBW-3220 is a novel reversible BTKi binding to BTK non-covalently. HBW-3220 has potent inhibitory effects on BTK wild-type and BTK mutants (C481S, C481R, T474I, T316A, etc.). HBW-3220 also has a superior preclinical profile, including better anti-tumor efficacy, PK properties and safety, validating its clinical study in cancer patients. Methods: This is a phase I dose-escalation study in patients with r/r B-cell non-Hodgkin's lymphoma. The dose escalation was performed with the accelerated titration and the 3+3 design. Adverse events (AEs) were assigned according to NCI Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Response assessment for chronic lymphocytic leukemia (CLL) was based on the iwCLL 2018 guidelines, for Waldenström macroglobulinemia (WM) was based on the IWWM- 7 consensus, and for all other lymphomas (such as small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), follicular lymphoma (FL), etc.) was based on the Lugano 2014 guidelines. Results: A total of 11 patients were enrolled, and the doses were 15, 30, 60, 90 or 120 mg QD. No dose-limiting toxicity (DLT) occurred in any patient, implicating good tolerability. AEs were similar to other BTKis. Common AEs (≥2 cases, grade 1-3) were neutropenia (n = 2), reduced platelet count (n = 3) and reduced white blood cell count (n = 2). Drug-related grade 3 AEs were neutropenia (n = 1) and pulmonary infection (n = 1). There was no AE leading to discontinuation or dose reduction. 8 patients underwent at least one response assessment, with 1 complete remission (CR) and 5 stable disease (SD). 1 patient (30 mg) with MZL achieved CR at the first response assessment, and her extranodal lesion (2cm*1cm) in the nasopharynx completely disappeared; she remains CR after 20 weeks of medication, and no obvious AEs has been observed! 3 patients in the 60 mg dose group (2 FL and 1 DLBCL) were assessed as SD during the first assessment, and all had tumor shrinkages! 1 MCL patient in the 90 mg dose group has had his lesion reduced by 43%. After oral administration of HBW-3220, the drug exposures show dose-dependent increases, and the time to maximum plasma concentration (Tmax) is 1-4 hours, and elimination half-life (T1/2) is 11-25 hours. Conclusions: The current data show that HBW-3220 is well tolerated and of efficacy in patients with B-cell lymphoma. Its clinical PK characteristics support once-a-day administration. Clinical trial information: ChiCTR20221130 ." @default.
• W4379281914 created "2023-06-05" @default.
• W4379281914 creator A5008121592 @default.
• W4379281914 creator A5008924675 @default.
• W4379281914 creator A5019650982 @default.
• W4379281914 creator A5061209676 @default.
• W4379281914 creator A5070515519 @default.
• W4379281914 creator A5081367802 @default.
• W4379281914 date "2023-06-01" @default.
• W4379281914 modified "2023-09-24" @default.
• W4379281914 title "Phase I clinical study of orally-dosed HBW-3220 in patients with relapsed/refractory B-cell lymphoma." @default.
• W4379281914 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e19532" @default.
• W4379281914 hasPublicationYear "2023" @default.
• W4379281914 type Work @default.
• W4379281914 citedByCount "0" @default.
• W4379281914 crossrefType "journal-article" @default.
• W4379281914 hasAuthorship W4379281914A5008121592 @default.
• W4379281914 hasAuthorship W4379281914A5008924675 @default.
• W4379281914 hasAuthorship W4379281914A5019650982 @default.
• W4379281914 hasAuthorship W4379281914A5061209676 @default.
• W4379281914 hasAuthorship W4379281914A5070515519 @default.
• W4379281914 hasAuthorship W4379281914A5081367802 @default.
• W4379281914 hasConcept C126322002 @default.
• W4379281914 hasConcept C143998085 @default.
• W4379281914 hasConcept C159654299 @default.
• W4379281914 hasConcept C170493617 @default.
• W4379281914 hasConcept C197934379 @default.
• W4379281914 hasConcept C203014093 @default.
• W4379281914 hasConcept C2776694085 @default.
• W4379281914 hasConcept C2777058707 @default.
• W4379281914 hasConcept C2777063308 @default.
• W4379281914 hasConcept C2777525834 @default.
• W4379281914 hasConcept C2777793932 @default.
• W4379281914 hasConcept C2777938653 @default.
• W4379281914 hasConcept C2778453870 @default.
• W4379281914 hasConcept C2778461978 @default.
• W4379281914 hasConcept C2778563104 @default.
• W4379281914 hasConcept C2779338263 @default.
• W4379281914 hasConcept C2779878957 @default.
• W4379281914 hasConcept C2779921676 @default.
• W4379281914 hasConcept C2780653079 @default.
• W4379281914 hasConcept C2781038049 @default.
• W4379281914 hasConcept C42362537 @default.
• W4379281914 hasConcept C502942594 @default.
• W4379281914 hasConcept C71924100 @default.
• W4379281914 hasConcept C90059517 @default.
• W4379281914 hasConceptScore W4379281914C126322002 @default.
• W4379281914 hasConceptScore W4379281914C143998085 @default.
• W4379281914 hasConceptScore W4379281914C159654299 @default.
• W4379281914 hasConceptScore W4379281914C170493617 @default.
• W4379281914 hasConceptScore W4379281914C197934379 @default.
• W4379281914 hasConceptScore W4379281914C203014093 @default.
• W4379281914 hasConceptScore W4379281914C2776694085 @default.
• W4379281914 hasConceptScore W4379281914C2777058707 @default.
• W4379281914 hasConceptScore W4379281914C2777063308 @default.
• W4379281914 hasConceptScore W4379281914C2777525834 @default.
• W4379281914 hasConceptScore W4379281914C2777793932 @default.
• W4379281914 hasConceptScore W4379281914C2777938653 @default.
• W4379281914 hasConceptScore W4379281914C2778453870 @default.
• W4379281914 hasConceptScore W4379281914C2778461978 @default.
• W4379281914 hasConceptScore W4379281914C2778563104 @default.
• W4379281914 hasConceptScore W4379281914C2779338263 @default.
• W4379281914 hasConceptScore W4379281914C2779878957 @default.
• W4379281914 hasConceptScore W4379281914C2779921676 @default.
• W4379281914 hasConceptScore W4379281914C2780653079 @default.
• W4379281914 hasConceptScore W4379281914C2781038049 @default.
• W4379281914 hasConceptScore W4379281914C42362537 @default.
• W4379281914 hasConceptScore W4379281914C502942594 @default.
• W4379281914 hasConceptScore W4379281914C71924100 @default.
• W4379281914 hasConceptScore W4379281914C90059517 @default.
• W4379281914 hasIssue "16_suppl" @default.
• W4379281914 hasLocation W43792819141 @default.
• W4379281914 hasOpenAccess W4379281914 @default.
• W4379281914 hasPrimaryLocation W43792819141 @default.
• W4379281914 hasRelatedWork W1021645331 @default.
• W4379281914 hasRelatedWork W2095408122 @default.
• W4379281914 hasRelatedWork W2234908256 @default.
• W4379281914 hasRelatedWork W2384638857 @default.
• W4379281914 hasRelatedWork W2419308557 @default.
• W4379281914 hasRelatedWork W2767548364 @default.
• W4379281914 hasRelatedWork W29500930 @default.
• W4379281914 hasRelatedWork W4362593813 @default.
• W4379281914 hasRelatedWork W4375865410 @default.
• W4379281914 hasRelatedWork W4379281914 @default.
• W4379281914 hasVolume "41" @default.
• W4379281914 isParatext "false" @default.
• W4379281914 isRetracted "false" @default.
• W4379281914 workType "article" @default.